Press "Enter" to skip to content

China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic Urothelial CarcinomaSecond approval of tislelizumab in China, first in solid tumor – BioSpace

admin 0

China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic Urothelial CarcinomaSecond approval of tislelizumab in China, first in solid tumor  BioSpace
“bladder cancer” – Google News

(Visited 2 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *